⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of EyePoint Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
EyePoint Pharmaceuticals
↗Watertown, Massachusetts, USA
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases. The company leverages its proprietary bioerodible Durasert® technology to create sustained-release drug delivery systems designed to improve patient outcomes and reduce the burden of frequent follow-up care.
Headquartered in Watertown, Massachusetts, EyePoint has transitioned from a commercial ophthalmic-products business to a concentrated clinical-stage developer. Its primary focus is the advancement of its lead product candidate, DURAVYU™ (vorolanib intravitreal insert), which is currently in Phase 3 clinical trials for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$5M-$10M
Founded:1987
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO
STOCK
Exchange:NASDAQ
Ticker:EYPT
Market Cap:$1.03B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule, Drug-device combination
Active Trials:4
Trial Phases:Phase 3: 4
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Alimera Sciences (divested YUTIQ rights)
COMPETITION
Position:Emerging
Competitors:Regeneron, Roche, Novartis, AbbVie
LEADERSHIP
Key Executives:
Jay S. Duker, M.D. - President & CEO
George O. Elston - EVP, CFO
Ramiro Ribeiro, M.D., Ph.D. - Chief Medical Officer
Board Members:Göran Ando, Nancy Lurker, Wendy DiCicco, Fred Hassan
LINKS
Website:eyepointpharma.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with EyePoint Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.